Anti-PD1/PD-L1 blocking strategies appear to be more effective for the treatment of lung cancers in patients with a history of smoking[49], which comprise a very small proportion of EGFR-mutated lung cancers but a significant proportion of tumors with high while type EGFR expression and high mutation density when compared to tumors that arise in oligo-smokers [50,51]. The gene discussed is EGFR; the disease is lung cancer.